14.81

0.47% 0.07

Biohaven Ltd (BHVN)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Perché BHVN Giù? Forum Previsione

Precedente Chiudi:

$14.74

Aprire:

$14.66

Volume 24 ore:

2.48M

Relative Volume:

1.32

Capitalizzazione di mercato:

$1.51B

Reddito:

Utile/perdita netta:

$-804.34M

Rapporto P/E:

-1.5739

EPS:

-9.41

Flusso di cassa netto:

$-531.06M

1 W Prestazione:

-5.31%

1M Prestazione:

-32.31%

6M Prestazione:

-67.81%

1 anno Prestazione:

-57.96%

Intervallo 1D:

$14.33

$15.18

Intervallo di 1 settimana:

$14.33

$15.94

Portata 52W:

$14.33

$55.70

Biohaven Ltd Stock (BHVN) Company Profile

Nome

Biohaven Ltd

Settore

Healthcare (1170)

Industria

Biotechnology (667)

Telefono

203-404-0410

Indirizzo

215 CHURCH STREET, NEW HAVEN, CT

Dipendente

256

Cinguettio

@biohavenpharma

Prossima data di guadagno

2022-11-07T13:30:00.000Z

Ultimi documenti SEC

BHVN's Discussions on Twitter

Confronta BHVN con altri titoli

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
BHVN Biohaven Ltd	14.81	1.60B	0	-804.34M	-531.06M	-9.41
ONC Beone Medicines Ltd Adr	245.58	26.10B	3.81B	-644.79M	-669.77M	-6.24
VRTX Vertex Pharmaceuticals Inc	442.05	111.96B	11.10B	-988.90M	-1.26B	-3.92
AKTX Akari Therapeutics Plc Adr	1.35	42.96M	0	0	0	0.00
VRNA Verona Pharma Plc Adr	81.20	6.39B	0	-153.72M	-103.81M	-2.00
REGN Regeneron Pharmaceuticals Inc	490.28	63.52B	14.09B	4.50B	2.96B	39.28

Biohaven Ltd Stock (BHVN) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2025-05-19	Downgrade	RBC Capital Mkts	Outperform → Sector Perform
2025-02-11	Iniziato	Deutsche Bank	Buy
2024-09-16	Iniziato	Jefferies	Buy
2024-09-04	Iniziato	Bernstein	Outperform
2024-07-24	Iniziato	Morgan Stanley	Overweight
2024-02-16	Iniziato	RBC Capital Mkts	Outperform
2024-02-06	Iniziato	UBS	Buy
2023-12-22	Iniziato	H.C. Wainwright	Buy
2023-12-08	Iniziato	Robert W. Baird	Outperform
2023-01-24	Iniziato	SVB Securities	Outperform
2023-01-04	Iniziato	JP Morgan	Overweight
2022-12-02	Iniziato	BTIG Research	Buy
2022-10-26	Aggiornamento	Cantor Fitzgerald	Neutral → Overweight
2022-10-12	Iniziato	Piper Sandler	Overweight
2022-08-19	Downgrade	Piper Sandler	Overweight → Neutral
2022-08-08	Downgrade	Wedbush	Outperform → Neutral
2022-05-11	Downgrade	SVB Leerink	Outperform → Mkt Perform
2021-10-19	Ripresa	Morgan Stanley	Equal-Weight
2021-08-10	Downgrade	UBS	Buy → Neutral
2021-08-03	Reiterato	Canaccord Genuity	Buy
2021-03-11	Iniziato	UBS	Buy
2020-12-15	Iniziato	H.C. Wainwright	Buy
2020-04-17	Iniziato	Cowen	Outperform
2020-02-10	Downgrade	Oppenheimer	Outperform → Perform
2020-02-06	Iniziato	Mizuho	Buy
2019-11-22	Iniziato	Wedbush	Outperform
2019-06-25	Reiterato	Canaccord Genuity	Buy
2019-05-06	Iniziato	Goldman	Buy
2019-04-09	Downgrade	Morgan Stanley	Overweight → Equal-Weight
2019-03-04	Reiterato	Needham	Buy
2018-07-03	Reiterato	Needham	Buy
2018-07-02	Reiterato	Needham	Buy
2018-04-05	Downgrade	Barclays	Overweight → Equal Weight
2018-02-22	Reiterato	Canaccord Genuity	Buy
2017-12-15	Iniziato	Canaccord Genuity	Buy
2017-10-03	Reiterato	Needham	Buy

Mostra tutto

Biohaven Ltd Borsa (BHVN) Ultime notizie

May 30, 2025

Biohaven stock hits 52-week low at $14.36 amid market challenges - Investing.com Australia

May 30, 2025

H.C. Wainwright maintains Buy on Biohaven stock, $54 price target - Investing.com Australia

May 30, 2025

H.C. Wainwright maintains Buy on Biohaven stock, $54 price target By Investing.com - Investing.com India

May 30, 2025

Biohaven Ltd. Receives Buy Rating from Douglas Tsao Amid Promising R&D Advancements and Strategic Developments - TipRanks

May 30, 2025

Biohaven Ltd. Receives Buy Rating Amidst Promising Developments and Strategic Advancements - TipRanks

May 30, 2025

May 29, 2025

Investors in Biohaven Ltd. (BHVN) Warned of Potential Securities FraudContact Levi & Korsinsky Today - ACCESS Newswire

May 29, 2025

Cowen reiterates Buy on Biohaven stock, maintains $75 target By Investing.com - Investing.com India

May 29, 2025

Biohaven Ltd. Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - marketscreener.com

May 29, 2025

Biohaven initiates global Phase 2/3 study of BHV-8000 - TipRanks

May 29, 2025

Biohaven (BHVN) Commences Innovative Phase 2/3 Parkinson's Drug Trial | BHVN Stock News - GuruFocus

May 29, 2025

TD Cowen on Biohaven Pharmaceutical Holding (BHVN): 'This Pipeline Is Impressive', 'Buy BHVN' - StreetInsider

May 29, 2025

Biohaven Enrolls First Patient into Phase 2/3 Trial in Early Parkinson's Disease, Targeting Neuroinflammation with Novel Brain-Penetrant TYK2/JAK1 Inhibitor - PR Newswire

May 29, 2025

Biohaven’s BHV-1400 shows promise in IgA nephropathy treatment By Investing.com - Investing.com South Africa

May 29, 2025

Optimistic Buy Rating for Biohaven Ltd. Amid Promising Pipeline and Regulatory Challenges - TipRanks

May 29, 2025

Biohaven Ltd.: Promising Pipeline and Undervaluation Justify Buy Rating - TipRanks

May 29, 2025

Biohaven Highlights Innovation and Advancement Across MoDE and TRAP Degrader Platform at R&D Day, Announcing Positive TRAP Degrader Data Achieving > 80% Sustained Reductions in Galactose-Deficient IgA1 (Gd-IgA1) with Potential First-in-Class - The Malaysian Reserve

May 29, 2025

Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Treat a Wide Variety of Tumors - The Malaysian Reserve

May 29, 2025

Biohaven Presents Oncology Program Updates and Preliminary Clinical Data Showcasing Innovative Trop2 and FGFR3 Antibody Drug Conjugates (ADCs) Incorporating Novel TopoIx Payload with Potential to Trea - StreetInsider

May 29, 2025